Enliven Therapeutics (ELVN) Change in Accured Expenses (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Change in Accured Expenses data on file, last reported at -$4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 78.96% year-over-year to -$4.5 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 865.84% YoY), and the FY2025 full-year result was -$496000.0, down 100.0% from the prior year.
• Change in Accured Expenses fell to -$4.5 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.8 million in Q4 2023 to a low of -$4.5 million in Q1 2026.
• A 5-year average of $239294.1 and a median of $387000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1098.19% in 2023, while the deepest fall reached 897.2% in 2023.
• Tracing ELVN's Change in Accured Expenses over 5 years: stood at $663000.0 in 2022, then surged by 621.27% to $4.8 million in 2023, then sank by 126.85% to -$1.3 million in 2024, then soared by 191.59% to $1.2 million in 2025, then tumbled by 479.68% to -$4.5 million in 2026.
• Business Quant data shows ELVN's Change in Accured Expenses at -$4.5 million in Q1 2026, $1.2 million in Q4 2025, and $814000.0 in Q3 2025.